Heart rate reduction as a therapeutic goal: focus on primary prevention

Heart rate reduction as a therapeutic goal: focus on primary prevention

Recently published studies have demonstrated a direct link between heart rate (HR) and prognosis across various populations and clinical groups, including elderly people, patients with arterial hypertension, myocardial infarction, and coronary artery stenting, overweight patients, or even young peop...

Full description

Bibliographic Details
Main Authors: Yu. A. Orlova, G. V. Makarova, G. V. Mikhailova, F. T. Ageev
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2012-02-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
heart rate
primary prevention
β-adrenoblockers
prognosis
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1706
id doaj-4943077cab714461abb8ee43fcc4df3f
record_format Article
spelling doaj-4943077cab714461abb8ee43fcc4df3f2021-07-28T13:50:54Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252012-02-01111899510.15829/1728-8800-2012-1-89-951424Heart rate reduction as a therapeutic goal: focus on primary preventionYu. A. Orlova0G. V. Makarova1G. V. Mikhailova2F. T. Ageev3A.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical ComplexЦентральная поликлиника ФСБ РФ, МоскваA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical ComplexA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical ComplexRecently published studies have demonstrated a direct link between heart rate (HR) and prognosis across various populations and clinical groups, including elderly people, patients with arterial hypertension, myocardial infarction, and coronary artery stenting, overweight patients, or even young people with relatively low cardiovascular risk levels. HR is considered as an additional independent risk factor (RF) of cardiovascular disease (CVD). However, thus far, pharmaceutical HR reduction has been demonstrated to improve prognosis only in patients with coronary heart disease or chronic heart failure. The results in CVD-free patients have been contradictory. The review discusses the potential of different HR-reducing therapeutic regimens, as a part of primary CVD prevention.https://cardiovascular.elpub.ru/jour/article/view/1706heart rateprimary preventionβ-adrenoblockersprognosis
collection DOAJ
language Russian
format Article
sources DOAJ
author Yu. A. Orlova
G. V. Makarova
G. V. Mikhailova
F. T. Ageev
spellingShingle Yu. A. Orlova
G. V. Makarova
G. V. Mikhailova
F. T. Ageev
Heart rate reduction as a therapeutic goal: focus on primary prevention
Кардиоваскулярная терапия и профилактика
heart rate
primary prevention
β-adrenoblockers
prognosis
author_facet Yu. A. Orlova
G. V. Makarova
G. V. Mikhailova
F. T. Ageev
author_sort Yu. A. Orlova
title Heart rate reduction as a therapeutic goal: focus on primary prevention
title_short Heart rate reduction as a therapeutic goal: focus on primary prevention
title_full Heart rate reduction as a therapeutic goal: focus on primary prevention
title_fullStr Heart rate reduction as a therapeutic goal: focus on primary prevention
title_full_unstemmed Heart rate reduction as a therapeutic goal: focus on primary prevention
title_sort heart rate reduction as a therapeutic goal: focus on primary prevention
publisher «SILICEA-POLIGRAF» LLC
series Кардиоваскулярная терапия и профилактика
issn 1728-8800
2619-0125
publishDate 2012-02-01
description Recently published studies have demonstrated a direct link between heart rate (HR) and prognosis across various populations and clinical groups, including elderly people, patients with arterial hypertension, myocardial infarction, and coronary artery stenting, overweight patients, or even young people with relatively low cardiovascular risk levels. HR is considered as an additional independent risk factor (RF) of cardiovascular disease (CVD). However, thus far, pharmaceutical HR reduction has been demonstrated to improve prognosis only in patients with coronary heart disease or chronic heart failure. The results in CVD-free patients have been contradictory. The review discusses the potential of different HR-reducing therapeutic regimens, as a part of primary CVD prevention.
topic heart rate
primary prevention
β-adrenoblockers
prognosis
url https://cardiovascular.elpub.ru/jour/article/view/1706
work_keys_str_mv AT yuaorlova heartratereductionasatherapeuticgoalfocusonprimaryprevention
AT gvmakarova heartratereductionasatherapeuticgoalfocusonprimaryprevention
AT gvmikhailova heartratereductionasatherapeuticgoalfocusonprimaryprevention
AT ftageev heartratereductionasatherapeuticgoalfocusonprimaryprevention
_version_ 1721271105502576640

Similar Items